Ludwig Institute (LICR)
The Ludwig Institute for Cancer Research Ltd is an international not-for-profit organization with a 40-year legacy of pioneering cancer discoveries. The Institute provides its scientists from around the world with the resources and the flexibility to realize the life-changing potential of their work and see their discoveries advance human health. This philosophy, combined with robust translational programs, maximizes the potential of breakthrough discoveries to be more attractive for commercial development. The Ludwig Institute conducts its own research and clinical trials, making it a bridge from the most basic questions of life to the most pressing needs of cancer care. Since its inception, the Institute has invested more than $1.8 billion of its own resources in cancer research, and has an endowment valued at $1.3 billion. The Institute's assets are managed by the Ludwig Institute Fund.
iTeos has entered into Research Collaboration and License Agreements on IDO1, TDO2 and Galectin-3 technology and patents developed by the Ludwig Institute.
iTeos and Adimab LLC are collaborating on the discovery, development and commercialization of multiple, antibody-based therapeutic programs, with Adimab using its antibody discovery and optimization platform to identify fully human therapeutic antibodies against targets selected by iTeos. All product development, including manufacturing and clinical trials, will be coordinated by iTeos.